Advertisement

Topics

Eyenovia Inc. Company Profile

09:14 EDT 14th August 2018 | BioPortfolio

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases. For more information, visit www.eyenoviabio.com.


News Articles [16 Associated News Articles listed on BioPortfolio]

Eyenovia's myopia drug advances to late-stage study

Eyenovia will commence in 2019 a late-stage study of MicroPine, a microtherapeutic formulation of atropine, in patients with  -More- 

MicroPine phase 3 trial for myopia to begin in 2019

The MicroPine program for the treatment of progressive myopia will begin a phase 3 pivotal study in 2019, according to a press release from Eyenovia.Eyenovia has received feedback that it will need to...

Eyenovia to Present at the 30th Annual ROTH Conference

NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its ...

Eyenovia Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology ...

Eyenovia Appoints Three Industry Veterans to Board of Directors

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piez...

Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference

NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-pri...

Eyenovia posts $5.1 million loss in 2017

Eyenovia reported a net loss of $2.2 million, or $0.84 per share, in the fourth quarter of 2017 compared with a net loss of $1.2 million, or $0.51 per share, in the fourth quarter of 2016, according t...

Eyenovia Announces Conference Call and Webcast for First Quarter 2018 Financial Results

NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Eyenovia MiDD Usability Study

This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Companies [2 Associated Companies listed on BioPortfolio]

Eyenovia Inc.

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for mic...

Eyenovia, Inc.

More Information about "Eyenovia Inc." on BioPortfolio

We have published hundreds of Eyenovia Inc. news stories on BioPortfolio along with dozens of Eyenovia Inc. Clinical Trials and PubMed Articles about Eyenovia Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eyenovia Inc. Companies in our database. You can also find out about relevant Eyenovia Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record